Merck, Moderna detail potential skin cancer vaccine progress
The drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Share:
